MarketIQ Analyst Report for Pro-Dex Inc

2361 MCGAW AVENUE, IRVINE, CA, US
PDEX

Last Updated: 19 Sep 2024

Executive Summary

Pro-Dex Inc. (PDEX) is a medical device company that designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers. The company has a market capitalization of $85.63 million and a trailing price-to-earnings (PE) ratio of 42.5. PDEX's latest stock price is $25.5, which is below its 52-week high of $29.99 but above its 52-week low of $14.51.

Company Overview

Pro-Dex Inc. was founded in 1987 and is headquartered in Irvine, California. The company's products are used in a variety of surgical procedures, including laparoscopic, robotic, and open surgery. PDEX's customers include medical device manufacturers, hospitals, and surgery centers.

Fundamental Analysis

PDEX's financial performance has been strong in recent years. The company's revenue has grown from $44.4 million in 2020 to $53.8 million in 2023. Net income has also increased from $2.3 million in 2020 to $3.3 million in 2023. PDEX's gross profit margin is 23.7%, and its operating margin is 15.7%. The company's return on assets (ROA) is 8.6%, and its return on equity (ROE) is 6.81%.

Technical Analysis

PDEX's stock price has been trending higher in recent months. The stock is currently trading above its 50-day and 200-day moving averages. The relative strength index (RSI) is 60, which indicates that the stock is overbought.

Short Term Outlook

PDEX's stock price is expected to continue to trend higher in the short term. The company's financial performance is strong, and the technical analysis indicates that the stock is in a bullish trend.

Long Term Outlook

PDEX's long-term outlook is positive. The company is a leader in the powered surgical instruments market, and its products are used in a variety of surgical procedures. The company's financial performance is strong, and its stock price is expected to continue to grow in the long term.

Analyst Recommendations

Analysts are bullish on PDEX's stock. The consensus analyst rating is "buy," and the average analyst target price is $30.00.